Relypsa Inc (RLYP)

[BigGreen101]

It has been tough to judge the hyperkalemia market size, which can be up to $6B in annual sales (over even greater IMO).

RLYP only needs 150,000 patients/year to have Veltassa be a billion dollar drug ($595/month treatment cost). Both ZS and RLYP have projected about 3 million people would be candidates for treatment. There are a lot more people with hyperkalemia, but not severe enough (without RAAS inhibitors) or are on dialysis (patient currently excluded).

One can do the math and project the potential maximum market. This market could be expanded to dialysis patient and pediatric in the future. JMO

A $2B offer gives $44/share
A $2.7B offer gives $60/share

AZN bought ZS for $2.7B. I think management is looking for something comparable or more even in this market since Veltassa from RLYP is FDA approved and ZS-9 was not.